Bangalore: Well known scientist, Dr Kalyanasundaram Subramanian has joined Syngene International. He was until recently serving as the Chief Scientific Officer at Strand Life Sciences. Popularly known as ‘Kas’, he lead Strand’s scientific and technical programs and coordinated the cross-divisional efforts in R&D. He headed the molecular diagnostics R&D efforts at Strand since 2003, and has over a decade of experience in modeling biological systems. Dr Kas’s interests lie in the field of genomics and systems biology.
Breaking this news, Dr Subramanian in his post on LinkedIn mentioned, “This is the end of an era, almost! After 14 wonderful years at Strand Life Sciences, I have now moved to Syngene International to set up a Bioinformatics business unit. I am excited to have with me the great team that built the virtual liver platform as well as the team that worked on data analytic services to the pharma industry.” On his new role, he added, “I am looking forward to growing this business within Syngene as well as providing integrated drug discovery and development services using Syngene’s amazing capabilities across drug development.”
An IIT – Bombay alumnus, Dr Subramanian went on to complete his MS in Chemical Engineering from the State University of New York College at Buffalo. Equipped with a PhD in Biomedical Engineering from Johns Hopkins University, Kas took up the position of Senior Scientist at Genetic Therapy Inc (Novartis) between 1997-2000, where he helped set-up a group to perform research in synthetic and hybrid vectors for gene delivery. Prior to Strand, Kas headed the Collaborative R&D group for immunology products at Entelos.
Syngene’s business is organized into three verticals – Dedicated R&D Centers, Discovery Services and Development and Manufacturing Services. During the first quarter of FY 2017, Syngene recorded robust growth in its Discovery Services and Development & Manufacturing Services. The company commissioned the first phase of its Syngene Research Centre (SRC), spread across 50,000 sq ft area. When fully commissioned, SRC will have a total area of 200,000 sq ft that will support integrated discovery and development programs. The company also commissioned its Viral Testing Facility in Bengaluru on 1st July 2016. The facility will provide niche services to support the viral testing requirements of the pharma and biotech sectors.